These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 35348806)

  • 1. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
    van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH
    Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
    Dos Santos RG; Hallak JE; Baker G; Dursun S
    J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
    Calder AE; Rausch B; Liechti ME; Holze F; Hasler G
    J Psychopharmacol; 2024 Oct; 38(10):873-886. PubMed ID: 39302087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the 5-HT
    Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
    Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
    ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Up-to-Date on clinical and preclinical studies of psilocybin therapy].
    Ibi D
    Nihon Yakurigaku Zasshi; 2024; 159(4):214-218. PubMed ID: 38945903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
    Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
    Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
    Sekssaoui M; Bockaert J; Marin P; Bécamel C
    Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
    Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
    J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.